Back to results
US 10,064,935 B2Granted
Human cytomegalovirus RNA vaccines
AssigneeModernaTX, Inc.
InventorsGiuseppe Ciaramella, Shinu John, Kambiz Mousavi
Life of this patent
Estimating the term…
Abstract
The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims20
A human cytomegalovirus (hCMV) vaccine comprising:
- (a) at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding a hCMV gH polypeptide;
- (b) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV gL polypeptide;
- (c) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL128 polypeptide;
- (d) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL130 polypeptide;
- (e) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL131A polypeptide;
- and (f) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV gB polypeptide, wherein the mRNA polynucleotides of (a)-(f) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine, and wherein the mRNA polynucleotides of (a)-(f) are not self-replicating RNA.
3 more elements
A human cytomegalovirus (hCMV) vaccine comprising:
- (a) at least one RNA polynucleotide comprising an open reading frame (ORF) that comprises the nucleotide sequence identified by SEQ ID NO:
- 108, (b) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO:
- 109, (c) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO:
- 110, (d) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO:
- 93, (e) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO:
- 112, and (f) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO:
- 113, wherein the RNA polynucleotides of (a)-(f) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine.
4 more elements
Dependencies are inferred from the claim text.